Cathepsin B in Osteoarthritis: Cytochemical and Histochemical Analysis of Human Femoral Head Cartilage
Overview
Authors
Affiliations
Objective: To localise the cysteine endopeptidase cathepsin B in chondrocytes and cartilage from normal and osteoarthritic (OA) human femoral heads in order to provide qualitative information on its cellular expression and distribution at possible sites of action.
Methods: OA articular cartilage was obtained at surgery for total hip replacement; control cartilage was obtained at postmortem. Chondrocytes were isolated by sequential enzymatic digestion and cathepsin B analysed by immunocytochemistry and activity staining with a fluorogenic substrate. Lysosomes were visualised by fluorescence microscopy after staining of living cells with acridine orange. Using a histochemical reaction, enzyme activity was measured in cryosections of full thickness cartilage.
Results: Chondrocytes from normal cartilage contained very few lysosomes and only a minor cell population was cathepsin B positive. A high proportion of chondrocytes from active OA cartilage contained a large number of lysosomes and an excess of cathepsin B in intracellular organelles; the enzyme was stored in an active form. In this respect, OA chondrocytes closely resembled normal cells that had been phenotypically modulated by serial subcultures. No cathepsin B activity could be detected by histochemistry in either chondrocytes or matrix of normal cartilage. While apparently intact and severely degraded OA cartilage was also cathepsin B negative, tissue at sites of active destruction and, particularly, at repair sites was highly positive.
Conclusion: The presence and the particular distribution of active cathepsin B in OA cartilage at 'more involved' sites suggest a pathological role for this enzyme in sustaining and perpetuating cartilage degradation. While other stimuli may also be responsible for cathepsin B expression in OA chondrocytes, the similarity with artificially modulated cells indicates fibroblastic metaplasia as a plausible mechanism.
Perez-Garcia S, Calamia V, Hermida-Gomez T, Gutierrez-Canas I, Carrion M, Villanueva-Romero R Int J Mol Sci. 2021; 22(12).
PMID: 34208590 PMC: 8235106. DOI: 10.3390/ijms22126441.
Chondroprotection and Molecular Mechanism of Action of Phytonutraceuticals on Osteoarthritis.
Sukhikh S, Noskova S, Ivanova S, Ulrikh E, Izgaryshev A, Babich O Molecules. 2021; 26(8).
PMID: 33924083 PMC: 8074261. DOI: 10.3390/molecules26082391.
Nasr S, Varshosaz J, Hajhashemi V Pharmacol Rep. 2020; 72(3):680-691.
PMID: 32274768 DOI: 10.1007/s43440-020-00099-x.
Hook G, Jacobsen J, Grabstein K, Kindy M, Hook V Front Neurol. 2015; 6:178.
PMID: 26388830 PMC: 4557097. DOI: 10.3389/fneur.2015.00178.
Molecular targets in arthritis and recent trends in nanotherapy.
Roy K, Kanwar R, Kanwar J Int J Nanomedicine. 2015; 10:5407-20.
PMID: 26345140 PMC: 4554438. DOI: 10.2147/IJN.S89156.